Reach Us +44-1647-403003
HDACIs, An Alternative Therapeutic Approach Human Breast Cancer Treatment, In Vivo And In Vitro | 22715
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

HDACIs, An alternative therapeutic approach human breast cancer treatment, in vivo and in vitro

4th World Congress on Cancer Science & Therapy

Soha M H and Sultan A S

Accepted Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.S1.035

Breast cancer is the most common cause of cancer and the second most common cause of death in women worldwide. Despite major recent advances in therapy, more effective approaches to the treatment and prevention are necessary. Histone deacetylase inhibitors (HDACIs) provide an alternative therapeutic approach for the treatment of breast cancer. The therapeutic potential of HDACIs stems from their capacity to selectively induce apoptosis in tumor cells. HDACIs show promise as a single anti-cancer drugthat given the range of molecular and biological responses andhave a minimal toxicity to normal cells. In the present study, we investigated and compared the anticancer effects of two structurally distinct HDACIs, Vorinostat (SAHA) and Valproic Acid (VPA) respectively. In addition, we tested the effect of VPA/SAHA as a combination treatment, using T-47Dhuman breast cancer cell line. Anticancer effects of tested drugs were assessed by MTT assay, western blotting analysis of expression levels of p53, β-catenin and cyclin D1. In addition, apoptotic induction and morphological characteristics of T-47D breast cancer cells upon treatment with SAHA, VPA and combined treatment byboth drugs were performed.Furthermore, the antitumor effect of SAHA was investigatedbyimmunohistochemical analysis to detectcyclin Dl expression in tumor tissues of MNU-induced breast carcinoma in vivo. In vivo model, breast tumor size was decreased and nuclear localization of cyclin D1profoundly was changedupon SAHA treatment. In vitro, SAHAshowed a strong inhibitory effect on cyclin D1 expression compared to VPAinT-47D cells. In addition, HDACIs- treated T-47D cancer cells suppressed the expression level of oncogenic β-catenin expression and enhancedtotal p53 expression. Furthermore, SAHA,VPA and VPA/ SAHA combined treatments induced morphological changes, apoptosis induction and DNA fragmentations. These results suggest that the combination treatment of SAHA and/or VPA exerts significant antitumor activity and could be a promising therapeutic candidate for human breast cancer treatment.
Soha M H is a lecturer assistant at the biochemistry department-Faculty of Science - Alexandria University, Egypt.
Relevant Topics